Evidence map›Paper›PMID 34550483›Full record

Trial reportMedical oncology (Northwood, London, England)2021

Docetaxel plus cisplatin in recurrent and/or metastatic non-squamous-cell head and neck cancer: a multicenter phase II trial.

Yoshinori Imamura, Kaoru Tanaka, Naomi Kiyota, Hidetoshi Hayashi, Ichiro Ota, Akihito Arai, Shigemichi Iwae, Shujiro Minami, Katsunari Yane, Tomoko Yamazaki and 8 more

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Medical oncology (Northwood, London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Observational
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 1 country.

Yoshinori ImamuraDepartment of Medical Oncology and Hematology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Kaoru TanakaDepartment of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-Sayama, Osaka, 589-8511, Japan.
Naomi KiyotaDepartment of Medical Oncology and Hematology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan. nkiyota@med.kobe-u.ac.jp.ORCID http://orcid.org/0000-0001-8021-6116
Hidetoshi HayashiDepartment of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-Sayama, Osaka, 589-8511, Japan.
Ichiro OtaDepartment of Otolaryngology-Head and Neck Surgery, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8521, Japan.
Akihito AraiDepartment of Otolaryngology, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji Kamigyo-ku, Kyoto, 602-8566, Japan.
Shigemichi IwaeDepartment of Head and Neck Surgery, Hyogo Cancer Center, 13-70 Kitaoujicho, Akashi, Hyogo, 673-8588, Japan.
Shujiro MinamiDepartment of Otolaryngology, National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo, 152-8902, Japan.
Katsunari YaneDepartment of Otolaryngology, Kindai University Nara Hospital, 1248-1 Otoda-cho, Ikoma, Nara, 630-0293, Japan.
Tomoko YamazakiDivision of Head and Neck Medical Oncology, Miyagi Cancer Center, 47-1 Nodayama, Medeshimashiode, Natori, Miyagi, 981-1293, Japan.
Yoshiaki NagataniDepartment of Medical Oncology and Hematology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Masanori ToyodaDepartment of Medical Oncology and Hematology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Takayuki TakahamaDepartment of Genome Biology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-Sayama, Osaka, 589-8511, Japan.
Kazuko SakaiDepartment of Genome Biology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-Sayama, Osaka, 589-8511, Japan.
Kazuto NishioDepartment of Genome Biology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-Sayama, Osaka, 589-8511, Japan.
Naoki OtsukiDepartment of Otolaryngology-Head and Neck Surgery, Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Ken-Ichi NibuDepartment of Otolaryngology-Head and Neck Surgery, Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Hironobu MinamiDepartment of Medical Oncology and Hematology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Kindai University · JPKobe University Hospital · JPKobe University · JPHyogo Prefectural Cancer Center · JPKyoto Prefectural University of Medicine · JPMiyagi Prefectural Hospital Organization · JPNara Medical University · JPTokyo Medical Center · JP

Funding

Ministry of Education, Culture, Sports, Science and Technology, Japan 17K11384Ministry of Education, Culture, Sports, Science and Technology, Japan 26462605
6 · The paper itself

Abstract

The clinical utility of systemic therapy and genomic profiling in non-squamous-cell head and neck cancer (NSCHNC) has not been fully elucidated. This phase II trial evaluated the efficacy and safety of docetaxel and cisplatin combination in the first-line setting. Eligibility criteria were recurrent and/or metastatic NSCHNC; progressive disease within the last 6 months; no prior systemic therapy; and ECOG performance status of 0-1. Patients received docetaxel (75 mg/m

Indexed as

AdultAgedAnaplastic Lymphoma KinaseAntineoplastic Combined Chemotherapy ProtocolsCisplatinDocetaxelFemaleHead and Neck NeoplasmsHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedNeoplasm Recurrence, LocalALK protein, humanAnaplastic Lymphoma KinaseCisplatinDocetaxelCisplatinDocetaxelNon-squamous-cell head and neck cancerPhase II trial

Identifiers

PMID34550483
OpenAlexW3199137677

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.